DS96432529 (Standard) is the analytical standard of
DS96432529 (
HY-145121). This product is intended for research and analytical applications.
DS96432529 is an orally active
CDK8 inhibitor with an
IC50 of 33 nM.
DS96432529 enhances
ALPase activity, with an
EC200 of 63 nM.
DS96432529 inhibits TNF-α-induced activation of the
RLR signaling pathway, activates
mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells.
DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models.
DS96432529 can be used in studies related to periodontitis and
osteoporosis.
0 ImagesDS96432529 (Standard) is the analytical standard of DS96432529 (HY-145121). This product is intended for research and analytical applications. DS96432529 is an orally active CDK8 inhibitor with an IC50 of 33 nM. DS96432529 enhances ALPase activity, with an EC200 of 63 nM. DS96432529 inhibits TNF-α-induced activation of the RLR signaling pathway, activates mitophagy, accelerates mineralized nodule formation, and suppresses the proliferation of periodontal ligament stem cells. DS96432529 promotes bone formation, alleviates ligation-induced alveolar bone loss, and increases bone mineral density in ovariectomized animal models. DS96432529 can be used in studies related to periodontitis and osteoporosis.
